The common deletion 657del5 in the Nibrin gene is not a major risk factor for B or T cell non-Hodgkin lymphoma in a pediatric population

被引：0
|
作者：
J Rischewski
P v Bismarck
H Kabisch
G Janka-Schaub
T Obser
R Schneppenheim
机构：
[1] University Children's Hospital,Department of Pediatric Haematology and Oncology
来源：
Leukemia | 2000年 / 14卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1528 / 1529
页数：1
相关论文
共 48 条
  • [41] MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians
    Bittenbring, Joerg
    Parisot, Frederique
    Wabo, Alain
    Mueller, Monika
    Kerschenmeyer, Lynn
    Kreuz, Markus
    Truemper, Lorenz
    Landt, Olfert
    Menzel, Alain
    Pfreundschuh, Michael
    Roemer, Klaus
    BMC CANCER, 2008, 8 (1)
  • [42] MDM2 gene SNP309 T/G and p53gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians
    Joerg Bittenbring
    Frédérique Parisot
    Alain Wabo
    Monika Mueller
    Lynn Kerschenmeyer
    Markus Kreuz
    Lorenz Truemper
    Olfert Landt
    Alain Menzel
    Michael Pfreundschuh
    Klaus Roemer
    BMC Cancer, 8
  • [43] Genetic variations in tumor necrosis factor related apoptosis-inducing ligand receptor-1 (TRAIL-R1) gene and the susceptibility to B-cell Non-Hodgkin Lymphoma (B-NHL) in Egypt (vol 32, pg 451, 2021)
    Khorshied, Mervat
    Soliman, Nohair
    Khorshid, Olab
    Bakr, Salwa
    CANCER BIOMARKERS, 2022, 33 (02) : 275 - 275
  • [44] Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT)
    Wei, J. I. A.
    Xiao, Min
    Mao, Zekai
    Cao, Yang
    Xiao, Yi
    Meng, Fankai
    Zhang, Yicheng
    Zhou, Jianfeng
    Huang, Liang
    BLOOD, 2021, 138
  • [45] CRC-403: A Phase 1/2 Study of bbT369, a Dual CD79a and CD20 Targeting CAR T Cell Drug Product with a Gene Edit, in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
    Locke, Frederick L.
    Miklos, David B.
    Tees, Michael
    Bees, Tina
    Li, Aojun
    Truppel-Hartmann, Anna
    Flinn, Ian W.
    BLOOD, 2022, 140 : 12716 - 12717
  • [46] Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma
    Popplewell, Leslie
    Wang, Xiuli
    Naranjo, Araceli
    Blanchard, Suzette
    Wagner, Jamie
    Wong, ChingLam
    Urak, Ryan
    Chang, Wen-Chung
    Khaled, Samer K.
    Siddiqi, Tanya
    Budde, Elizabeth E.
    Xu, Jingying
    Chang, Brenda
    Thomas, Sandra H.
    Riddell, Stanley R.
    Brown, Christine
    Jensen, Michael C.
    Forman, Stephen J.
    BLOOD, 2015, 126 (23)
  • [47] Characterization of t(3;6)(q27;p21) breakpoints in B-cell non-Hodgkin's lymphoma and construction of the histone H4/BCL6 fusion gene, leading to altered expression of Bcl-6
    Kurata, M
    Maesako, Y
    Ueda, C
    Nishikori, M
    Akasaka, T
    Uchiyama, T
    Ohno, H
    CANCER RESEARCH, 2002, 62 (21) : 6224 - 6230
  • [48] Characterization of t(3;6)(q27;p21) breakpoints in B-cell non-Hodgkin's lymphoma and construction of histone H4/BCL6 fusion gene leading to altered expression of Bcl-6.
    Kurata, M
    Maesako, Y
    Ueda, C
    Nishikori, M
    Akasaka, T
    Uchiyama, T
    Ohno, H
    BLOOD, 2002, 100 (11) : 530A - 530A
12345